EGFR and glioblastoma: The antitumor activity of i6A has been shown in several reports as either acting with antiangiogenic 60 and immunomodulatory activities 61, 62; later, the same group depicted the role of i6A as an anticancer in glioblastoma multiforme (GMB), the most common brain tumor type 63, revealing that i6A causes epidermal growth factor receptor (EGFR) proteasome degradation and consequent deregulation 64.